Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Bullboard Posts
Comment by Majictraderon Mar 27, 2020 12:29pm
98 Views
Post# 30853358

RE:RE:RE:RE:RE:RE:RE:Cipher Pharma has price target cut at Stifel Canada

RE:RE:RE:RE:RE:RE:RE:Cipher Pharma has price target cut at Stifel Canada6 cents to reach the .90 target. WOW what a genius. Sorry for the sarcasm :). I re-read the conf call transcript. Its clear that they are working with Bausch to resolve this. So dont think it will be a long drawn process or expensive one. Other than that they lost some sales momentum. With COVID they have time to resolve it. I think it will be sooner than later. Also, with Abrobica LD, very very imp point is to convert existing prescriptions to LD formulation and that can't be made generic. So LD is protected. I am sure Sun is one of their US partners that have shown interest in marketing tie-up. Sun has presence in Canada as well. And they had a great partnership with CPH for this one product. Sunny Days!
Bullboard Posts